Clinical Scorecard: Tirzepatide's Impact on the Incidence of Pulmonary Embolism and Deep Vein Thrombosis: Findings from a Multicenter Cohort Study in the U.S.
At a Glance
Category
Detail
Condition
Venous thromboembolism (VTE)
Key Mechanisms
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Target Population
Adults with type 2 diabetes and overweight or obesity.
Care Setting
Population-based retrospective cohort study.
Key Highlights
Tirzepatide use was associated with a significantly lower 12-month risk of pulmonary embolism compared to lifestyle intervention alone.
The risk of deep vein thrombosis was also significantly lower with tirzepatide use.
No significant difference was observed for superficial vein thrombosis.
Findings remained significant in a 90-day landmark analysis.
Tirzepatide showed a lower risk of deep vein thrombosis compared to semaglutide.
Guideline-Based Recommendations
Diagnosis
Monitor for signs and symptoms of venous thromboembolism in patients with type 2 diabetes and obesity.
Management
Consider tirzepatide as a treatment option for patients with type 2 diabetes and obesity, weighing thromboembolic risks.
Monitoring & Follow-up
Regularly assess patients for thromboembolic events during and after treatment initiation.
Risks
Be aware of the potential for thromboembolic events, particularly in patients with risk factors.
Patient & Prescribing Data
Adults with type 2 diabetes and overweight or obesity.
Tirzepatide may reduce the risk of pulmonary embolism and deep vein thrombosis in this population.
Clinical Best Practices
Utilize propensity score matching to control for confounding variables in observational studies.
Conduct regular follow-ups to monitor for adverse events in patients starting new therapies.
Preoperative use was associated with fewer revisions and no increase in short-term complications among patients with obesity, although benefits appeared concentrated in select subgroups.
In two population-based cohorts, metabolically unhealthy status generally showed higher dementia risk estimates, while metabolically healthy obesity was not associated with increased risk in primary analyses.
